Trinity eyes coag/infection testing buy after fundraising
This article was originally published in Clinica
Executive Summary
Trinity Biotech president Brendan Farrell told Clinica the company was looking for acquisition opportunities in the haemostasis and infectious disease testing markets, following a £22.5m ($41m) fundraising.